

Availability of screening test for detection of *Candida auris* (*C. auris*) from colonized patients

Effective 20 June 2023, DMC University Laboratories will offer a molecular test as a screening tool for the detection of *Candida auris* from patients with high index of suspension for colonization by this new emerging pathogen.

Due to clinical needs and the lack of an FDA-cleared and commercially available molecular assay for detection of *C. auris*, DMC University Laboratories has developed a sensitive nucleic acid test for screening the patients for colonization by *C. auris*. The assay uses real-time PCR and detects a unique and specific region of *C. auris* genome. The test has not been cleared/approved by FDA. This test was validated and its performance characteristics verified by DMC University Laboratories.

C. auris PCR is for screening purposes and should not be used for detection of *C. auris* in clinical specimens such as urine, sputum, wound, and blood.

Acceptable specimen:

Swab of groin and axilla collected in ESwab™ tube.

Expected turn-around time:

Assay is performed daily. Expected turn-around time is one day.

CIS Test Name: Candida Auris by PCR
Sunquest / Antrim Test Code: CAURIS
CPT code: 87481

For questions or concerns, please contact:

Fadi Gammou, MT, Microbiology Division Manager (313) 745-2134
Hossein Salimnia, PhD, Technical Director, Microbiology (313) 745-2130
Marilynn Fairfax, MD, PhD, Medical Director, DMC UL (313) 745-4188
Timothy Kennedy, MD, CLIA Director, DMCUL (313) 745-4571